ID: ALA2147771

Max Phase: Preclinical

Molecular Formula: C21H29N7OS

Molecular Weight: 427.58

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccn2)n1

Standard InChI:  InChI=1S/C21H29N7OS/c1-16-12-20(28(24-16)19-4-2-3-5-22-19)26-8-6-25(7-9-26)17-13-18(23-14-17)21(29)27-10-11-30-15-27/h2-5,12,17-18,23H,6-11,13-15H2,1H3/t17-,18-/m0/s1

Standard InChI Key:  MKJRNYHUGVCOAT-ROUUACIJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 427.58

Molecular Weight (Monoisotopic): 427.2154

AlogP: 0.96

#Rotatable Bonds: 4

Polar Surface Area: 69.53

Molecular Species: BASE

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.38

CX LogP: 0.79

CX LogD: -1.17

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.78

Np Likeness Score: -1.72

References

1. Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N, Sekiguchi S, Ishige T, Shima K, Nabeno M, Abe Y, Anabuki J, Soejima A, Yoshida K, Takashina Y, Ishii S, Kiuchi S, Fukuda S, Tsutsumiuchi R, Kosaka K, Murozono T, Nakamaru Y, Utsumi H, Masutomi N, Kishida H, Miyaguchi I, Hayashi Y..  (2012)  Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.,  20  (19): [PMID:22959556] [10.1016/j.bmc.2012.08.012]

Source

Source(1):

• Scientific Literature